When was GenomeDx Biosciences founded?

GenomeDx Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is GenomeDx Biosciences located?

GenomeDx Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does GenomeDx Biosciences have?

As of Dec 31, 2022, GenomeDx Biosciences has 159 employees, reflecting a 13% year-over-year decline in headcount.

Is GenomeDx Biosciences a funded company?

GenomeDx Biosciences is a funded company, having raised a total of $69.7M across 14 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 2009.

When was the latest funding round of GenomeDx Biosciences?

GenomeDx Biosciences' latest funding was a $***** Series C round on May 15, 2020, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.84B in funding in 2026 to date.

Where does GenomeDx Biosciences rank among its competitors?

GenomeDx Biosciences ranks 11th amongst 124 active competitors, of which 28 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was KromaTiD, which secured $8M in Jul, 2025.

Who are the top competitors of GenomeDx Biosciences?

GenomeDx Biosciences' top competitors include Artera, PathogenDX and MDxHealth. Among them, KromaTiD secured the most recent funding round in July, 2025.

GenomeDx Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

GenomeDx develops and commercializes genomic tests for urologic cancers. Its proprietary Decipher GRID platform is a clinically annotated genomic expression database for urological cancers. Its flagship product predicts the probability of metastasis of prostrate cancer after surgery by measuring expression levels of 22 different biomarkers.

Website: genomedx.com
Social
Part Of
Registered Address: San Diego, California

Key Metrics

Founded Year

2008

Location

San Diego, United States

Stage

Series C

Total Funding

$69.7M in 14 rounds

Latest Funding Round

Series C, May 15, 2020, $*****

Investors

Merck Global Health Innovation Fund & 7 more

Ranked

11^th among 124 active competitors

Employee Count

159 as on Dec 31, 2022

Similar Companies

Artera & 172 more

View GenomeDx Biosciences' full profile

GenomeDx Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
GENOME DX BIOSCIENCES CORP CIN: 990373279 , United States, Active	Dec 31, 1999	-	92 (As on Dec 31, 2020)	-

GenomeDx Biosciences has raised a total funding of $69.7M over 14 rounds. Its first funding round was on Jun 2009. GenomeDx Biosciences has 8 institutional investors.

Here is the list of recent funding rounds of GenomeDx Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 15, 2020	5916781	Series C	4814418	4845221	8281620	7626128
May 15, 2020	9034539	Conventional Debt	1610862	1907317	5420848	7938157
Apr 10, 2019	9556098	Series C	5345845	5529155	4575940	9857570

Access funding benchmarks and valuations. Sign up today!

View details of GenomeDx Biosciences's funding rounds and investors

The founders of GenomeDx Biosciences is Timothy Triche.

Here are the details of GenomeDx Biosciences' key team members:

Timothy Triche: Co-Founder & Chief Medical Officer of GenomeDx Biosciences.

View details of GenomeDx Biosciences's Founder profiles and Board Members

GenomeDx Biosciences' employee count trend

GenomeDx Biosciences has 159 employees as of Dec 22. The total employee count is 14.0% lower than what it was in Dec 21. Here is GenomeDx Biosciences's employee count trend over the years:

Employee count trend for GenomeDx Biosciences

Uncover GenomeDx Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GenomeDx Biosciences include Artera, PathogenDX and MDxHealth. Here is the list of Top 10 competitors of GenomeDx Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, EDBI & 23 others	68/100
2nd	PathogenDX 2014, Tucson (United States), Series B	Provider of DNA-based pathogen testing kits	$11.6M	Entourage Effect Capital, Altitude Investment Management ... & 11 others	61/100
3rd	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Kreos Capital, Eiffel Investment Group & 13 others	60/100
4th	Agendia 2003, Irvine (United States), Series F	Provider of genomic diagnostic products for the treatment of cancer	$123M	Athyrium Capital Management, Van Herk Groep ... & 9 others	59/100
5th	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Gates, Oracle & 1 others	58/100
6th	InDevR 2003, Boulder (United States), Acquired	Manufacturer of biotherapeutics, vaccines and diagnostic products	$16M	Adjuvant Capital, BioMerieux & 2 others	57/100
7th	KromaTiD 2007, Fort Collins (United States), Series C	Provider of molecular and genetic tests for detection of disease-causing mutations	$15.4M	Broadoak Capital Partners, First Capital Ventures ... & 5 others	56/100
8th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Altos Ventures Management, Venture Kick & 3 others	55/100
9th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	53/100
10th	Akonni 2003, Frederick (United States), Series C	Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification	$39.7M	Righton, Choosemaryland.org & 5 others	49/100
11th	GenomeDx Biosciences 2008, San Diego (United States), Series C	Genomic tests for urologic cancers	$69.7M	CRG, Tekla Capital Management & 6 others	46/100